Reactivation of Chagas disease among heart transplant recipients in the United States, 2012‐2016

• Published in: Transplant infectious disease Vol. 20; no. 6; pp. e12996 - n/a
• Main Authors: Gray, Elizabeth B., La Hoz, Ricardo M., Green, Jaime S., Vikram, Holenarasipur R., Benedict, Theresa, Rivera, Hilda, Montgomery, Susan P.
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.12.2018
• Subjects: Activation; Adult; Aged; Allografts - parasitology; Allografts - pathology; Cardiomyopathy; Chagas Cardiomyopathy - epidemiology; Chagas Cardiomyopathy - parasitology; Chagas Cardiomyopathy - pathology; Chagas Cardiomyopathy - surgery; Chagas disease; Congestive heart failure; Coronary artery disease; Female; Follow-Up Studies; Heart; Heart - parasitology; Heart Failure - epidemiology; Heart Failure - parasitology; Heart Failure - pathology; Heart Failure - surgery; heart transplant; Heart transplantation; Heart Transplantation - adverse effects; Humans; Immunosuppression; Immunosuppression Therapy - adverse effects; Immunosuppression Therapy - methods; Male; Middle Aged; Monitoring; Myocarditis; Myocardium - pathology; Patients; Polymerase chain reaction; Preempting; reactivation; Recurrence; Risk Factors; Transplantation; Transplants & implants; Trypanosoma cruzi; Trypanosoma cruzi - isolation & purification; United States - epidemiology; Vector-borne diseases; United States; United States > US; Chagas disease; heart transplant; reactivation; Trypanosoma cruzi
• ISSN: 1398-2273; 1399-3062; 1399-3062
• DOI: 10.1111/tid.12996

Background Heart transplantation has been shown to be a safe and effective intervention for progressive cardiomyopathy from chronic Chagas disease. However, in the presence of the immunosuppression required for heart transplantation, the likelihood of Chagas disease reactivation is significant. Reactivation may cause myocarditis resulting in allograft dysfunction and the rapid onset of congestive heart failure. Reactivation rates have been well documented in Latin America; however, there is a paucity of data regarding the risk in non‐endemic countries. Methods We present our experience with 31 patients with chronic Chagas disease who underwent orthotopic heart transplantation in the United States from 2012 to 2016. Patients were monitored following a standard schedule. Results Of the 31 patients, 19 (61%) developed evidence of reactivation. Among the 19 patients, a majority (95%) were identified by laboratory monitoring using polymerase chain reaction testing. One patient was identified after the onset of clinical symptoms of reactivation. All subjects with evidence of reactivation were alive at follow‐up (median: 60 weeks). Conclusions Transplant programs in the United States are encouraged to implement a monitoring program for heart transplant recipients with Chagas disease. Our experience using a preemptive approach of monitoring for Chagas disease reactivation was effective at identifying reactivation before symptoms developed.